Yves A. DeClerck - Publications

Affiliations: 
Pathobiology University of Southern California, Los Angeles, CA, United States 
Area:
Oncology, Pharmacology, Pathology, Molecular Biology

90 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Blavier L, Yang RM, DeClerck YA. The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives. Cancers. 12. PMID 33050533 DOI: 10.3390/cancers12102912  0.312
2020 Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, Mark MT, Steiner L, Benito-Martin A, Lucotti S, Di Giannatale A, ... ... DeClerck YA, et al. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell. PMID 32795414 DOI: 10.1016/J.Cell.2020.07.009  0.331
2019 Kubala MH, DeClerck YA. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer and Metastasis Reviews. 38: 483-492. PMID 31734763 DOI: 10.1007/S10555-019-09806-4  0.376
2019 Wu HW, Sheard MA, Malvar J, Fernandez GE, DeClerck YA, Blavier L, Shimada H, Theuer CP, Sposto R, Seeger RC. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31068371 DOI: 10.1158/1078-0432.Ccr-18-3358  0.309
2018 Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, DeClerck YA. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. Cell Reports. 25: 2177-2191.e7. PMID 30463014 DOI: 10.1016/J.Celrep.2018.10.082  0.342
2017 Kubala MH, DeClerck YA. Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment. Journal of Visualized Experiments. PMID 29286360 DOI: 10.3791/56333  0.356
2017 Hadjidaniel MD, Muthugounder S, Hung LT, Sheard MA, Shirinbak S, Chan RY, Nakata R, Borriello L, Malvar J, Kennedy RJ, Iwakura H, Akamizu T, Sposto R, Shimada H, DeClerck YA, et al. Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget. 8: 91516-91529. PMID 29207662 DOI: 10.18632/Oncotarget.21066  0.441
2017 Nakata R, Shimada H, Fernandez GE, Fanter R, Fabbri M, Malvar J, Zimmermann P, DeClerck YA. Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells. Journal of Extracellular Vesicles. 6: 1332941. PMID 28717423 DOI: 10.1080/20013078.2017.1332941  0.39
2017 Lifshitz V, Priceman SJ, Li W, Cherryholmes G, Lee H, Makovski-Silverstein A, Borriello L, DeClerck YA, Yu H. Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Induced and Acquired Chemoresistance. Molecular Cancer Therapeutics. PMID 28716816 DOI: 10.1158/1535-7163.Mct-17-0379  0.36
2017 Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Malvar J, Blavier L, Shimada H, Asgharzadeh S, Seeger RC, DeClerck YA. Cancer-Associated Fibroblasts Share Characteristics and Pro-tumorigenic Activity with Mesenchymal Stromal Cells. Cancer Research. PMID 28687621 DOI: 10.1158/0008-5472.Can-16-2586  0.481
2017 DeClerck YA, Pienta KJ, Woodhouse EC, Singer DS, Mohla S. The Tumor Microenvironment at a Turning Point Knowledge Gained Over the Last Decade, and Challenges and Opportunities Ahead: A White Paper from the NCI TME Network. Cancer Research. 77: 1051-1059. PMID 28209610 DOI: 10.1158/0008-5472.Can-16-1336  0.331
2017 Kubala MH, Placencio VR, DeClerck YA. Abstract 3061: Tumor-derived PAI-1 promotes macrophage M2 polarization by stimulating an autocrine IL-6 /STAT3 pathway Cancer Research. 77: 3061-3061. DOI: 10.1158/1538-7445.Am2017-3061  0.386
2015 Borriello L, Seeger RC, Asgharzadeh S, DeClerck YA. More than the genes, the tumor microenvironment in neuroblastoma. Cancer Letters. PMID 26597947 DOI: 10.1016/J.Canlet.2015.11.017  0.368
2015 Placencio VR, Ichimura A, Miyata T, DeClerck YA. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. Plos One. 10: e0133786. PMID 26207899 DOI: 10.1371/Journal.Pone.0133786  0.44
2015 Placencio VR, DeClerck YA. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Research. 75: 2969-74. PMID 26180080 DOI: 10.1158/0008-5472.Can-15-0876  0.381
2015 HaDuong JH, Blavier L, Baniwal SK, Frenkel B, Malvar J, Punj V, Sposto R, DeClerck YA. Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis. International Journal of Cancer. Journal International Du Cancer. 137: 797-809. PMID 25648303 DOI: 10.1002/Ijc.29465  0.41
2015 Nakata R, Borriello L, Fabbri M, Shimada H, Declerck YA. Abstract 5076: Tumor cell-derived exosomes educate bone marrow mesenchymal stromal cells toward a protumorigenic function Cancer Research. 75: 5076-5076. DOI: 10.1158/1538-7445.Am2015-5076  0.395
2014 Solari V, Borriello L, Turcatel G, Shimada H, Sposto R, Fernandez GE, Asgharzadeh S, Yates EA, Turnbull JE, DeClerck YA. MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. Cancer Research. 74: 5999-6009. PMID 25164011 DOI: 10.1158/0008-5472.Can-13-2513  0.446
2014 Borriello L, DeClerck YA. [Tumor microenvironment and therapeutic resistance process]. MéDecine Sciences : M/S. 30: 445-51. PMID 24801042 DOI: 10.1051/Medsci/20143004021  0.464
2014 Bergfeld SA, Blavier L, DeClerck YA. Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Molecular Cancer Therapeutics. 13: 962-75. PMID 24502925 DOI: 10.1158/1535-7163.Mct-13-0400  0.44
2014 Borriello L, Nakata R, Wu H, Seeger RC, DeClerck YA. Abstract 4869: Bone marrow-derived stromal cells contribute to a protumorigenic inflammatory environment that promotes drug resistance Cancer Research. 74: 4869-4869. DOI: 10.1158/1538-7445.Am2014-4869  0.453
2014 Solari V, Borriello L, Fernandez GE, Shimada H, Sposto R, Asgharzadeh S, Yates EA, Turnbull JE, Declerck YA. Abstract 3963: MYCN-dependent expression of sulfatase2 regulates neuroblastoma cell survival Cancer Research. 74: 3963-3963. DOI: 10.1158/1538-7445.Am2014-3963  0.453
2013 Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Research. 73: 4965-77. PMID 23913938 DOI: 10.1158/0008-5472.Can-13-0661  0.384
2013 Ara T, Nakata R, Sheard MA, Shimada H, Buettner R, Groshen SG, Ji L, Yu H, Jove R, Seeger RC, DeClerck YA. Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Research. 73: 3852-64. PMID 23633489 DOI: 10.1158/0008-5472.Can-12-2353  0.355
2013 HaDuong JH, Blavier L, Baniwal SK, Frenkel B, DeClerck YA. Abstract 2601: Interaction between bone marrow mesenchymal stem cells and neuroblastoma cells leads to osteoblastogenesis and VEGFA expression. Cancer Research. 73: 2601-2601. DOI: 10.1158/1538-7445.Am2013-2601  0.416
2013 Placencio VR, Miyata T, DeClerck YA. Abstract 1548: Pharmacologic inhibition of PAI-1 increases apoptosis and inhibits macrophage migration in cancer. Cancer Research. 73: 1548-1548. DOI: 10.1158/1538-7445.Am2013-1548  0.458
2013 DeClerck YA. Abstract 1524: Heparan sulfate and Sulf-2 expression in neuroblastoma. Cancer Research. 73: 1524-1524. DOI: 10.1158/1538-7445.Am2013-1524  0.42
2012 Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. Journal of the National Cancer Institute. 104: 1470-84. PMID 22984202 DOI: 10.1093/Jnci/Djs377  0.409
2012 DeClerck YA. Desmoplasia: a response or a niche? Cancer Discovery. 2: 772-4. PMID 22969116 DOI: 10.1158/2159-8290.Cd-12-0348  0.382
2012 Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Research. 72: 2473-80. PMID 22414581 DOI: 10.1158/0008-5472.Can-12-0122  0.434
2012 Yang F, Jove V, Buettner R, Xin H, Wu J, Wang Y, Nam S, Xu Y, Ara T, DeClerck YA, Seeger R, Yu H, Jove R. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biology & Therapy. 13: 534-41. PMID 22406995 DOI: 10.4161/Cbt.19603  0.425
2012 Silverman AM, Nakata R, Shimada H, Sposto R, DeClerck YA. A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Cancer Research. 72: 2228-38. PMID 22389450 DOI: 10.1158/0008-5472.Can-11-2165  0.415
2012 Baniwal SK, Shah PK, Shi Y, Haduong JH, DeClerck YA, Gabet Y, Frenkel B. Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells Osteoporosis International. 23: 1399-1413. PMID 21881969 DOI: 10.1007/S00198-011-1728-5  0.34
2012 Fang H, Placencio VR, DeClerck YA. Abstract 2462: Pro-tumorigenic activity of plasminogen activtor inhibitor-1 through an anti-apoptotic function Cancer Research. 72: 2462-2462. DOI: 10.1158/1538-7445.Am2012-2462  0.433
2012 Bergfeld SA, Blavier L, Moats RA, DeClerck YA. Abstract 1478: Bone marrow mesenchymal stem cells suppress tumor cell apoptosis and are selectively recruited to early-stage tumors Cancer Research. 72: 1478-1478. DOI: 10.1158/1538-7445.Am2012-1478  0.443
2011 Isono M, Suzuki T, Hosono K, Hayashi I, Sakagami H, Uematsu S, Akira S, DeClerck YA, Okamoto H, Majima M. Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. Life Sciences. 88: 693-700. PMID 21324324 DOI: 10.1016/J.Lfs.2011.02.008  0.312
2011 Ara T, Nakata R, Shimada H, Buettner R, Seeger RC, Yu H, Jove R, DeClerck YA. Abstract 508: Signal transduction and activator of transcription (STAT) 3 is necessary for environment-mediated drug resistance Cancer Research. 71: 508-508. DOI: 10.1158/1538-7445.Am2011-508  0.398
2011 Yang F, Jove V, Buettner R, Xin H, Nam S, Ara T, DeClerck YA, Seeger RC, Yu H, Jove R. Abstract 4340: Sorafenib induces growth arrest and apoptosis in neuroblastoma cells via inhibition of JAK2/STAT3 and MEK1/2/MAPK (p44/42) signaling pathways Cancer Research. 71: 4340-4340. DOI: 10.1158/1538-7445.Am2011-4340  0.431
2010 Blavier L, Lazaryev A, Shi XH, Dorey FJ, Shackleford GM, DeClerck YA. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biology & Therapy. 10: 198-208. PMID 20534975 DOI: 10.4161/Cbt.10.2.12193  0.417
2010 Bergfeld SA, DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Reviews. 29: 249-61. PMID 20411303 DOI: 10.1007/S10555-010-9222-7  0.464
2010 Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. European Journal of Cancer (Oxford, England : 1990). 46: 1223-31. PMID 20335016 DOI: 10.1016/J.Ejca.2010.02.026  0.391
2010 Silverman AM, Fukaya Y, Shimada H, Groshen SG, DeClerck YA. Abstract 557: Galectin-3 binding protein produced by neuroblastoma cells stimulates the expression of interleukin-6 in bone marrow mesenchymal cells Cancer Research. 70: 557-557. DOI: 10.1158/1538-7445.Am10-557  0.405
2010 Fang H, DeClerck YA. Abstract 518: Plasminogen activator inhibitor-1 (PAI-1) protects tumor cells from extrinsic apoptosis Cancer Research. 70: 518-518. DOI: 10.1158/1538-7445.Am10-518  0.433
2009 Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. The Journal of Clinical Investigation. 119: 1524-36. PMID 19411762 DOI: 10.1172/Jci37869  0.451
2009 Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Research. 69: 329-37. PMID 19118018 DOI: 10.1158/0008-5472.Can-08-0613  0.367
2008 Chantrain CF, Feron O, Marbaix E, DeClerck YA. Bone marrow microenvironment and tumor progression. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 1: 23-35. PMID 19308682 DOI: 10.1007/S12307-008-0010-7  0.408
2008 Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, Martial JA, DeClerck YA. Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis Cancer Cell. 14: 324-334. PMID 18835034 DOI: 10.1016/J.Ccr.2008.08.012  0.415
2008 Fukaya Y, Shimada H, Wang LC, Zandi E, DeClerck YA. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. The Journal of Biological Chemistry. 283: 18573-81. PMID 18450743 DOI: 10.1074/Jbc.M803115200  0.388
2007 Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Research. 67: 9346-55. PMID 17909043 DOI: 10.1158/0008-5472.Can-06-4508  0.426
2007 Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. The Journal of Clinical Investigation. 117: 2702-12. PMID 17710228 DOI: 10.1172/Jci30751  0.467
2007 Wall SJ, Zhong ZD, DeClerck YA. The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest. The Journal of Biological Chemistry. 282: 24471-6. PMID 17553787 DOI: 10.1074/Jbc.M702697200  0.386
2006 Ara T, DeClerck YA. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Reviews. 25: 645-57. PMID 17160711 DOI: 10.1007/S10555-006-9028-9  0.424
2006 Mouchess ML, Sohara Y, Nelson MD, DeCLerck YA, Moats RA. Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model. Journal of Computer Assisted Tomography. 30: 525-34. PMID 16778634 DOI: 10.1097/00004728-200605000-00030  0.379
2006 Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Reviews. 25: 35-43. PMID 16680570 DOI: 10.1007/S10555-006-7887-8  0.489
2006 Blavier L, Lazaryev A, Dorey F, Shackleford GM, DeClerck YA. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Research. 66: 2691-9. PMID 16510589 DOI: 10.1158/0008-5472.Can-05-2919  0.431
2006 Chantrain CF, Henriet P, Jodele S, Emonard H, Feron O, Courtoy PJ, DeClerck YA, Marbaix E. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. European Journal of Cancer (Oxford, England : 1990). 42: 310-8. PMID 16406506 DOI: 10.1016/J.Ejca.2005.11.010  0.376
2005 Wall SJ, Werner E, Werb Z, DeClerck YA. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen Journal of Biological Chemistry. 280: 40187-40194. PMID 16186104 DOI: 10.1074/Jbc.M508226200  0.426
2005 Sohara Y, Shimada H, DeClerck YA. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Letters. 228: 203-9. PMID 15975706 DOI: 10.1016/J.Canlet.2005.01.059  0.389
2005 Reynolds CP, Sun BC, DeClerck YA, Moats RA. Assessing growth and response to therapy in murine tumor models. Methods in Molecular Medicine. 111: 335-50. PMID 15911989 DOI: 10.1385/1-59259-889-7:335  0.398
2005 Blavier L, Declerck YA. Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy. Cancer Cell. 7: 408-9. PMID 15894261 DOI: 10.1016/J.Ccr.2005.04.024  0.431
2005 Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, Shimada H, Coussens LM, Declerck YA. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Research. 65: 3200-8. PMID 15833851 DOI: 10.1158/0008-5472.Can-04-3770  0.475
2005 Sohara Y, Shimada H, Minkin C, Erdreich-Epstein A, Nolta JA, DeClerck YA. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Research. 65: 1129-35. PMID 15734993 DOI: 10.1158/0008-5472.Can-04-2853  0.373
2004 DeClerck Y. Focus on the cell membrane: the need for dissociation and detachment in tumoral invasion. Cancer Biology & Therapy. 3: 632-633. PMID 15326373 DOI: 10.4161/Cbt.3.7.1027  0.376
2004 Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerck YA, Gomer CJ. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Research. 64: 2328-32. PMID 15059880 DOI: 10.1158/0008-5472.Can-04-0071  0.465
2004 DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, Padarathsingh M. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. The American Journal of Pathology. 164: 1131-9. PMID 15039201 DOI: 10.1016/S0002-9440(10)63200-2  0.468
2004 Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA. Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment Cancer Research. 64: 1675-1686. PMID 14996727 DOI: 10.1158/0008-5472.Can-03-0160  0.459
2004 Zucker S, Hymowitz M, Conner C, DeClerck Y, Cao J. TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. Experimental Cell Research. 293: 164-74. PMID 14729066 DOI: 10.1016/J.Yexcr.2003.10.007  0.375
2004 Zhao H, Bernardo MM, Osenkowski P, Sohail A, Pei D, Nagase H, Kashiwagi M, Soloway PD, DeClerck YA, Fridman R. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. The Journal of Biological Chemistry. 279: 8592-601. PMID 14681236 DOI: 10.1074/Jbc.M308708200  0.348
2003 Chantrain CF, DeClerck YA, Groshen S, McNamara G. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 51: 151-8. PMID 12533523 DOI: 10.1177/002215540305100203  0.318
2001 Blavier L, Lazaryev A, Groffen J, Heisterkamp N, DeClerck YA, Kaartinen V. TGF-beta3-induced palatogenesis requires matrix metalloproteinases. Molecular Biology of the Cell. 12: 1457-66. PMID 11359935 DOI: 10.1091/Mbc.12.5.1457  0.365
2001 Toth M, Bernardo MM, Gervasi DC, Soloway PD, Wang Z, Bigg HF, Overall CM, DeClerck YA, Tschesche H, Cher ML, Brown S, Mobashery S, Fridman R. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. The Journal of Biological Chemistry. 275: 41415-23. PMID 10998420 DOI: 10.1074/Jbc.M006871200  0.353
2000 Moats R, Ma LQ, Wajed R, Sugiura Y, Lazaryev A, Tyszka M, Jacobs R, Fraser S, Nelson MD, DeClerck YA. Magnetic resonance imaging for the evaluation of a novel metastatic orthotopic model of human neuroblastoma in immunodeficient mice. Clinical & Experimental Metastasis. 18: 455-61. PMID 11592302 DOI: 10.1023/A:1011827122126  0.363
2000 Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proceedings of the National Academy of Sciences of the United States of America. 97: 10026-31. PMID 10944199 DOI: 10.1073/Pnas.170290997  0.405
2000 DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. European Journal of Cancer. 36: 1258-1268. PMID 10882864 DOI: 10.1016/S0959-8049(00)00094-0  0.432
2000 Zhong ZD, Hammani K, Bae WS, DeClerck YA. NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. The Journal of Biological Chemistry. 275: 18602-10. PMID 10764764 DOI: 10.1074/Jbc.M001389200  0.334
1999 Blavier L, Henriet P, Imren S, Declerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Annals of the New York Academy of Sciences. 878: 108. PMID 10415723 DOI: 10.1111/J.1749-6632.1999.Tb07677.X  0.348
1999 Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. Apmis. 107: 111-119. PMID 10190287 DOI: 10.1111/J.1699-0463.1999.Tb01533.X  0.476
1998 MacDonald TJ, DeClerck YA, Laug WE. Urokinase induces receptor mediated brain tumor cell migration and invasion. Journal of Neuro-Oncology. 40: 215-226. PMID 10066093 DOI: 10.1023/A:1006150506789  0.455
1998 Luo MP, Gomperts B, Imren S, DeClerck YA, Ito M, Velicescu M, Felix JC, Dubeau L. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. Gynecologic Oncology. 67: 277-84. PMID 9441775 DOI: 10.1006/Gyno.1997.4880  0.343
1998 Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty AJ, Cao J. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). The Journal of Biological Chemistry. 273: 1216-22. PMID 9422789 DOI: 10.1074/Jbc.273.2.1216  0.376
1997 DeClerck YA, Imren S, Montgomery AMP, Mueller BM, Reisfeld RA, Laug WE. Proteases and protease inhibitors in tumor progression Advances in Experimental Medicine and Biology. 425: 89-97. PMID 9433492 DOI: 10.1007/978-1-4615-5391-5_9  0.442
1997 Blavier L, DeClerck YA. Tissue inhibitor of metalloproteinases-2 is expressed in the interstitial matrix in adult mouse organs and during embryonic development. Molecular Biology of the Cell. 8: 1513-1527. PMID 9285822 DOI: 10.1091/Mbc.8.8.1513  0.326
1997 Ko YC, Langley KE, Mendiaz EA, Parker VP, Taylor SM, DeClerck YA. The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity. Biochemical and Biophysical Research Communications. 236: 100-5. PMID 9223434 DOI: 10.1006/Bbrc.1997.6859  0.354
1997 MacDonald TJ, DeClerck YA, Laug WE. 512 Role of serine proteases in brain tumor invasion Journal of Pediatric Hematology Oncology. 19: 366. DOI: 10.1097/00043426-199707000-00046  0.347
1996 Lim YT, Sugiura Y, Laug WE, Sun B, Garcia A, DeClerck YA. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. Journal of Cellular Physiology. 167: 333-40. PMID 8613475 DOI: 10.1002/(Sici)1097-4652(199605)167:2<333::Aid-Jcp18>3.0.Co;2-8  0.391
1994 DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. European Journal of Cancer. 30: 2170-2180. PMID 7857719 DOI: 10.1016/0959-8049(94)00460-M  0.376
1993 DeClerck YA, Yean TD, Lee Y, Tomich JM, Langley KE. Characterization of the functional domain of tissue inhibitor of metalloproteinases-2 (TIMP-2). The Biochemical Journal. 289: 65-9. PMID 8424773 DOI: 10.1042/Bj2890065  0.312
1990 Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of Collagenolytic Activity and Metastasis of Tumor Cells by a Recombinant Human Tissue Inhibitor of Metalloproteinases Journal of the National Cancer Institute. 82: 589-595. PMID 2156082 DOI: 10.1093/Jnci/82.7.589  0.471
1988 DeClerck YA. Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. Archives of Biochemistry and Biophysics. 265: 28-37. PMID 2843102 DOI: 10.1016/0003-9861(88)90367-0  0.369
1985 DeClerck YA, Lee C. Collagen Biosynthesis in Human Neuroblastoma Cell Lines: Evidence for Expression of Glial Cell Properties Journal of the National Cancer Institute. 75: 431-439. DOI: 10.1093/Jnci/75.3.431  0.369
Show low-probability matches.